<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. *)
Pharmakinetics Laboratories, Inc.
---------------------------------
(Name of Issuer)
Common Stock, par value $.001 per share
---------------------------------------
(Title of Class of Securities)
71713-11-06
--------------
(CUSIP Number)
Bob E. Lehman, Esq.
Lehman & Eilen
50 Charles Lindbergh Boulevard, Suite 505
Uniondale, New York 11553
(516) 222-0888
--------------
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communication)
July 8, 1996
------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(3) or (4), check the following
box |_|.
Check the following box if a fee is being paid with the statement
|X|. (A fee is not required only if the reporting person: (1) has a previous
statement on file reporting beneficial ownership of more than five percent of
the class of securities described in Item 1; and (2) has filed no amendment
subsequent thereto reporting beneficial ownership of five percent of less of
such class.) (See Rule 13d-7).
Note: Six copies of this statement, including all exhibits, should be
filed with the Commission. See Rule 13d-1(a) for other parties to whom
copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required on this cover page shall not be deemed to be
"filed" for the purpose of Section 18 of the Securities Exchange Act of 1934
("Act") or otherwise subject to the liabilities of that section of the Act but
shall be subject to all other provisions of the Act (however, see the Notes).
<PAGE>
CUSIP NO. 71713-11-06 13D Page 2 of 5 Pages
1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE
PERSON: Robert A. Mackie, Jr., Social Security No. ###-##-####
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |X|
3. SEC USE ONLY
4. SOURCE OF FUNDS: PF
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEM 2(d) or 2(e)
6. CITIZENSHIP OR PLACE OF ORGANIZATION: U.S.
7. SOLE VOTING POWER: 192,383
8. SHARED VOTING POWER: 644,645
9. SOLE DISPOSITIVE POWER: 192,383
10. SHARED DISPOSITIVE POWER: 644,645
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 644,645
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:
|_|
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 5.28%
14. TYPE OF REPORTING PERSON: IN
<PAGE>
CUSIP NO. 71713-11-06 13D Page 3 of 5 Pages
1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE
PERSON: R.A. Mackie & Co., L.P., Fed. I.D. No. 13-3553219
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |X|
3. SEC USE ONLY
4. SOURCE OF FUNDS: WC
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEM 2(d) or 2(e)
6. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware
7. SOLE VOTING POWER:
8. SHARED VOTING POWER: 452,262
9. SOLE DISPOSITIVE POWER:
10. SHARED DISPOSITIVE POWER: 452,262
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 452,262
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:
|_|
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 3.71%
14. TYPE OF REPORTING PERSON: BD
<PAGE>
CUSIP NO. 71713-11-06 13D Page 4 of 5 Pages
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
PHARMAKINETICS LABORATORIES, INC.
---------------------------------
(Name of Company)
Item 1. Security and Issuer.
--------------------
The title of the class of equity security to which this statement
relates is the common stock, $.001 par value per share ("Common Stock"), of
Pharmakinetics Laboratories, Inc., a Maryland corporation (the "Company"),
whose principal executive offices are located at 302 West Fayette Street,
Baltimore, Maryland 21201.
Item 2. Identity and Background
-----------------------
This statement is filed by Robert A. Mackie, Jr. and R.A. Mackie & Co.,
L.P., a Delaware limited partnership. Mr. Mackie and R.A. Mackie & Co., L.P.
each maintain a business address at 18 North Astor Street, Irvington, New
York 10533. Mr. Mackie is the sole shareholder, director and executive
officer of R.A. Mackie & Co., Inc., the general partner of R.A. Mackie & Co.,
L.P. R.A. Mackie & Co., L.P. is a broker-dealer registered under the
Securities Act of 1934, as amended, and a member of the National Association
of Securities Dealers Regulatory, Inc. During the last five years, neither
Mr. Mackie nor R.A. Mackie & Co., L.P. has been convicted in a criminal
proceeding nor been a party to a civil proceeding of a judicial or adminis-
trative body of competent jurisdiction subjecting him or it, as the case may
be, to a judgement, decree or final order enjoining future violations of, or
prohibiting or mandating activities subject to, Federal or State securities
laws or finding any violation with respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration
-------------------------------------------------
The 192,383 shares of Common Stock owned by Mr. Mackie were purchased
with his own personal funds in open market transactions. The 452,262 shares of
Common Stock owned by R.A. Mackie & Co., L.P. were purchased with its working
capital in open market transactions.
Item 4. Purpose of the Transaction
--------------------------
The shares of Common Stock purchased by Mr. Mackie and R.A. Mackie &
Co., L.P. were acquired for investment purposes only.
Item 5. Interest in Securities of the Issuer
------------------------------------
(a) Mr. Mackie is the beneficial and sole owner of 192,383 shares of
Common Stock of the Company. Such 192,383 shares constitute approximately
1.58% of the shares of the Company's Common Stock outstanding as of July 8,
1996. R.A. Mackie & Co., L.P. is the beneficial and sole owner of 452,262
shares of Common Stock, constituting approximately 3.71% of the shares of the
<PAGE>
CUSIP NO. 71713-11-06 13D Page 5 of 5 Pages
Company's Common Stock outstanding as of July 8, 1996. By virtue of Mr.
Mackie's control over R.A. Mackie & Co., L.P., Mr. Mackie and R.A. Mackie &
Co., L.P. have an aggregate beneficial ownership equal to 644,645 shares of
Common Stock, or 5.29% of the shares of the Company's Common Stock outstanding
as of July 8, 1996.
(b) Mr. Mackie has the sole power to vote, or direct the vote, and
the sole power to dispose, or direct the disposition, of the 192,383 shares of
Common Stock owned by him and shares with R.A. Mackie & Co., L.P. the power to
vote, or direct the vote, and the power to dispose, or direct the disposition,
of the 452,262 shares of Common Stock owned by R.A. Mackie & Co., L.P.
(c) Mr. Mackie has not engaged in any transactions in the Company's
common stock during the 60 days prior to the July 9, 1996 date of this
Report. R.A. Mackie & Co., L.P. engaged in the following transactions in the
Company's common stock during the 60 days prior to the July 9, 1996 date of
this Report:
July 8, 1996.............Purchased 148,721 shares at $.25 a share
July 8, 1996.............Purchased 25,000 shares at $.375 a share
July 8, 1996.............Purchased 25,000 shares at $.3125 a share
Item 6. Contracts, Arrangements, Understandings or
Relationships with Respect to Securities of the Issuer
------------------------------------------------------
Not applicable.
Item 7. Material to be Filed as Exhibits
--------------------------------
Not applicable.
Signatures
After reasonable inquiry and to the best of his and its knowledge and
belief, the undersigned certify that the information set forth in this
statement is true, complete and correct.
Dated: As of July 9, 1996
R.A. Mackie & Co., L.P.
By: R.A. Mackie & Co., Inc.
By: /s/ Robert A. Mackie, Jr. /s/ Robert A. Mackie, Jr.
------------------------------- --------------------------------
Robert A. Mackie, Jr. Robert A. Mackie, Jr.,
Individually
